Sign in Subscribe
Pharmaceutical industry

Somaxon Pharmaceuticals Inc. (SOMX) Investment Report: Insights and Analysis

Strategic Insights

— 1 min read

Somaxon Pharmaceuticals Inc. (SOMX), a specialty pharmaceutical company, has recently undergone an investment report by BeaconEquity.com, which includes financial, comparative, and investment analyses, as well as relevant industry information. The report focuses on Somaxon's lead drug candidate, Silenor (doxepin), which has completed four phase III clinical trials for the treatment of insomnia. This is significant given that approximately 40 million people in the United States suffer from chronic sleep disorders, with 30 million more experiencing varying levels of insomnia.

Key Takeaways:

  • Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the research, development, marketing, and commercialization of proprietary drug therapies for psychiatric and neurological disorders.
  • Silenor (doxepin), Somaxon's lead drug candidate, has completed four phase III clinical trials for the treatment of insomnia, with the active ingredient doxepin showing promise in treating deep, restful sleep.
  • Approximately 40 million people in the United States suffer from chronic sleep disorders, with 30 million more experiencing varying levels of insomnia, highlighting the market potential for Silenor.
  • Doxepin's efficacy in functioning as an antagonist at 5-HT2a sites, promoting sleep, and its unique action on this receptor may provide a patent advantage for Somaxon, enabling successful commercialization of Silenor.
  • Comparing Somaxon to other pharmaceutical companies such as GlaxoSmithKline plc. (GSK), Sanofi-Aventis (SNY), and King Pharmaceuticals (KG) is essential for investors to consider the company's position in the market.

Statistics:

  • Approximately 40 million people in the United States suffer from chronic sleep disorders.
  • 30 million people in the United States experience varying levels of insomnia.
  • 65% of respondents in the 2007 Sleep in America Poll reported having trouble sleeping a couple of times per week.
  • Silenor's active ingredient, doxepin, functions as an antagonist at 5-HT2a sites, promoting sleep.
  • Doxepin has shown unique efficacy in promoting deep, restful sleep.

Sources:

  • Beacon Equity Research (2009)
  • Somaxon Pharmaceuticals Inc. (SOMX)
  • GlobeNewswire
  • Comtex SmarTrend Alert
  • Sanofi-Aventis (SNY)
  • GlaxoSmithKline plc. (GSK)
  • King Pharmaceuticals (KG)
  • Mylan Inc. (MYL)
  • Life Technologies Corp. (LIFE)

Read more